What molecule is targeted by suvorexant?
['Suvorexant is the first DORA to be approved and has demonstrated efficacy at decreasing both time to sleep onset and increasing total sleep time compared with placebo. ', 'Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.', 'CONCLUSION: Suvorexant is the first dual orexin receptor antagonist approved for the treatment of insomnia. ', 'Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.', ' The human OX2 receptor (OX2R) belongs to the β branch of the rhodopsin family of GPCRs, and can bind to diverse compounds including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant. ', 'Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.', 'Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.', 'The neurotransmitter systems on which the development of these agents were based included serotonin for ondansetron and lorcaserin, dopamine for varenicline, substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant. The indications were chemotherapy-induced nausea and vomiting for ondansetron and aprepitant, smoking cessation for varenicline, weight loss for lorcaserin, and insomnia for suvorexant and ramelteon.', 'Suvorexant, a dual orexin receptor antagonist for the management of insomnia.', 'Suvorexant, a dual orexin receptor antagonist for the management of insomnia.', 'The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved.', 'Suvorexant helps in decreasing wakefulness by counteracting orexin activity.', ' The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved.', 'Hypnotic drug development has arguably become more focused in recent years, particularly upon the highly anticipated novel target, the orexin (hypocretin) system. Merck&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012.']
['Suvorexant is a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.']
['orexin']